Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the reshoring of pharmaceutical manufacturing.
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules Read More »
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’ Read More »
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy Read More »
Staffers for Sen. Chuck Grassley, R-Iowa, dove into 50,000 pages of documentation from UnitedHealth for the new report, which accuses the company of maintaining a workforce dedicated to upcoding.
UnitedHealth ‘aggressively’ gaming Medicare Advantage, Senate investigation finds Read More »
The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that work by stimulating the tibial nerve.
Boston Scientific to buy incontinence device maker Valencia Read More »
The physician lobby surveyed 64 medical societies and found that most of them were worried about nurses, physician assistants and other practitioners getting more freedom to provide care this year.
Doctors focused on scope of practice, Medicaid cuts in state legislatures this year: AMA Read More »
Edwards terminated the deal after the Federal Trade Commission moved to block the acquisition due to anticompetitive concerns.
Edwards calls off JenaValve buyout after court halts deal Read More »
Transactions involving providers and related services increased 57% year over year, spurred by healthcare IT deals, according to Bain & Company.
Healthcare private equity dealmaking boosted by IT in 2025: report Read More »
The company unveiled the appointment alongside news of the departure of its chief commercial officer.
Illumina names former NIH genomics director as chief medical officer Read More »
While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast Read More »
